Plain-English translation of NCT05474092 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →This trial is following patients who receive the Aeson Total Artificial Heart system, a device designed to take over the work of a failing heart. Researchers want to confirm that the device works safely and effectively in real-world settings, and to track how well patients do while waiting for a heart transplant or after receiving one.
Advanced heart failure can be life-threatening, and some patients cannot wait for a donor heart or are not candidates for transplant. This study exists to confirm that the artificial heart device is a safe and reliable option to keep these patients alive and as healthy as possible.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the artificial heart device through surgery and then be monitored regularly by your medical team for up to two years. During this time, you would have follow-up visits to check how well the device is working, assess your heart and kidney function, evaluate your quality of life, and watch for any complications. Researchers will track whether you remain stable on the device, whether you eventually receive a transplant, and how you recover afterward.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Germany
Enrollment target
~95 participants
Started
November 2021
Primary completion
May 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elisabeth Vacher
Carmat SAS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.